OncoMatch/Neuroendocrine Tumor (NET)/MEN1
Neuroendocrine Tumor (NET)MEN1 Clinical Trials
1 recruiting trials·Updated daily from ClinicalTrials.gov
MEN1 mutations occur in approximately 35–40% of pancreatic NETs (pNETs) and define a subgroup with distinct epigenetic biology driven by menin loss. Loss of menin disrupts H3K4 methylation and epigenetic regulation. Menin inhibitors have established clinical activity in KMT2A/NPM1-rearranged leukemia, but MEN1-loss pNET is not yet a mature clinical trial axis; translational rationale exists but recruiting MEN1-selected pNET trials are uncommon. Most pNET trials enroll unselected by MEN1 status.
Top recruiting
Top recruiting MEN1 Neuroendocrine Tumor (NET) trials
Ranked by phase and US site count.
See all trials matched to your profile →Other Neuroendocrine Tumor (NET) biomarkers
Browse other molecular targets with active Neuroendocrine Tumor (NET) trials.